Name (Synonyms) | Correlation | |
---|---|---|
drug2699 | Standard of Care (Intravenous access) Wiki | 1.00 |
There is one clinical trial.
The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.
Description: successful placement of intravascular device
Measure: Success rate of first intravascular access attempt Time: 1 dayDescription: time to successful access
Measure: time to successful access Time: 1 dayDescription: number of attempts to successful access
Measure: number of attempts to successful access Time: 1 dayDescription: time to therapy including but not limited to time to fluids, antibiotics, and antiarrythmics
Measure: time to infusion Time: 1 dayDescription: complication rates
Measure: complication rates Time: 1 dayDescription: the rate of survival to hospital admission
Measure: ROSC Time: 1 day